SR-B1 RHDL DIRECTED NANOPARTICLES AS A DRUG DELIVERY SYSTEM AGAINST TRIPLE NEGATIVE BREAST CANCER

Purpose: Triple Negative Breast Cancer (TNBC), is a heterogeneous group of tumors with diverse histology, molecular uniqueness and response to treatment. As a result of ineffective treatments, TNBC tumors often progress to metastatic lesions in the brain and lung. Brain metastases of invasive breast cancer are associated with 1 and 2 year survival rate of 20% and < 2% respectively. Current anti-HER2 or hormone positive targeted breast cancer treatments do not benefit TNBC patients; consequently, these patients rely primarily on chemotherapy. Alternative targeted therapies are urgently needed to improve survival for TNBC patients. This study is focused on developing a new approach for filling the current void in effective treatment for TNBC patients. Methods: Cells were seeded and treated with free drug and drug loaded rHDl particle for 24 hours. Cell Viability was determined using the cell viability assay CCK8. 96 well plates were read at 450nm Results: Using the CCK8 cell viability assay preliminary data reveals the potential of Temsirolimus loaded rHDL nanoparticles to reduce the effective concentration at lower doses vs. the free drug in the MDA-MB-231 cell line. Conclusions: rHDL particles are small non-immunogenic nanoparticles that have the potential to decrease the side effects that accompany high concentrations of chemotherapeutic drugs. This study proposes the using the mTOR inhibitor Temsirolimus encapsulated into the rHDL nanoparticle as an effective treatment against TNBC vs the free drug.